Tomahawk, WI 06/05/2014 (Basicsmedia) – Roger Hawley, the emeritus CEO of Zogenix, Inc. (NASDAQ:ZGNX) unloaded 25,078 company shares in an open-market transaction on June 03, 2014. Priced at $2.10 per share, the stocks were sold off at a total valuation of $52,663.80. Post-completion of this sell out, the CEO is deemed to own 1,24,447 shares, at a net value of $2,529,339. However, the share prices tumbled down soon afterward!

Decrease In Short Interest

Zogenix, Inc. (NASDAQ:ZGNX) also witnesses a stark decrease in its short interests between April 30 and May 15, 2014. Total short interest at April 30, 2014 stood at 20,271,501 shares, whereas it dropped by 6.3%, reducing to 18,987,265 shares as of May 15! It was analyzed that the company has short sold 15.8% of its shares off late.

Quarterly Review

ZGNX issued its net quarterly estimates on May 08, 2014. The company announced about notching up $0.20 EPS in the last quarter, lower than the company’s earnings of $0.17 per share, during Q1-2013. On the contrary, Zogenix, Inc. (NASDAQ:ZGNX) reported about gaining total revenues of $7.70 million during the last quarter. The revenue generation has surged up almost 10.0%, year over year. The pharmaceutical company propounded that it expects to touch the $0.64 EPS mark during the FY 2014.

ZGNX has a 52 week trading history that depicts a trough of 1.25 and a high of 5.19! It has around 139.54 million shares that undergo trading, daily. The company that harps on means to manufacture medicines with the righteous use of technology has also reported a net market capitalization of $253.96 million.

Sumatriptan Injection Sales

Zogenix, Inc. (NASDAQ:ZGNX) reported on May 19, 2014, about a purported closure of the prior-announced sales of the SUMAVEL DosePro Needle-Free Delivery System to Endo International plc (NASDAQ:ENDP).

Cash Endowed

This Sumatriptan Injection that cures the treatment of pain-related disorders pertaining to the Central Nervous System was previously decided to be sold off to ENDP at a whopping $85 million in ready cash and other associated milestone payments, summing up to $20 million.

Debt Repaid

Following the transaction, the worldwide sales and allied rights for SUMAVEL DosePro is now reserved with ENDP. The closing of this sale aided Zogenix, Inc. (NASDAQ:ZGNX) repay its outstanding debts amounting to nearly 40 million!

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.